How to Get Tresiba in Vermont

What Is Tresiba and Why Vermont Clinicians Prescribe It

Insulin degludec (brand name Tresiba) is a basal insulin with a half-life exceeding 25 hours and a clinical duration of action beyond 42 hours, making it the longest-acting basal insulin currently on the US market. Vermont endocrinologists and primary care clinicians prescribe it for adults and children (age 1 and older) with type 1 or type 2 diabetes who need once-daily basal coverage. Its flat pharmacokinetic profile reduces day-to-day glucose variability compared with insulin glargine U-100. [1]

The DEVOTE trial (N=7,637) compared insulin degludec with insulin glargine U-100 in high-cardiovascular-risk patients with type 2 diabetes over a median of 2 years. Degludec was non-inferior on major adverse cardiovascular events (MACE) and produced a 40% lower rate of severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [2] That hypoglycemia finding matters for Vermont patients who live in rural areas where emergency services may be 30 or more minutes away.

The FDA-approved prescribing information lists starting doses of 10 units once daily for insulin-naive type 2 patients and a unit-for-unit conversion from other basal insulins for patients already on basal therapy. [3] Vermont prescribers generally follow the American Diabetes Association (ADA) Standards of Care, which state that "the choice of insulin regimen should be individualized based on patient and disease factors." [4]

Vermont Telehealth Rules for Tresiba Prescriptions

Vermont permits telehealth prescribing of Schedule V and non-scheduled drugs, which includes insulin degludec. A Vermont-licensed prescriber may write a Tresiba prescription after a synchronous audio-video visit without a prior in-person encounter, provided the visit meets the standard of care. [5] This is governed by Vermont Board of Medical Practice guidelines and aligns with the Vermont Telehealth Law (18 V.S.A. Chapter 221). [6]

Telehealth platforms operating in Vermont must verify prescriber licensure in the state. The Vermont Office of Professional Regulation maintains a public license lookup. Patients should confirm their telehealth provider holds an active Vermont license before scheduling. [7]

A typical telehealth visit for a new Tresiba prescription runs 20 to 40 minutes and covers diabetes history, current medications, recent A1C and fasting glucose, kidney function (eGFR), and cardiovascular history. The prescriber will also review any prior insulin regimen and calculate the starting degludec dose per the FDA label. [3] After the visit, the electronic prescription goes directly to the patient's chosen Vermont pharmacy or a mail-order pharmacy licensed in Vermont. The whole process, from scheduling to prescription transmission, often takes less than 48 hours on telehealth platforms with same-day or next-day appointment availability.

Labs Required Before Starting Tresiba in Vermont

Most Vermont prescribers order the same baseline panel before initiating any new basal insulin. The ADA Standards of Care recommend checking A1C every 3 months until glycemic targets are met, then every 6 months. [4] Before the first prescription, clinicians typically want results from the following tests, ideally within the past 90 days.

A1C establishes baseline glycemic control. Fasting plasma glucose or a recent continuous glucose monitor (CGM) download gives real-time context. A comprehensive metabolic panel (CMP) screens for renal impairment: insulin degludec does not require dose adjustment for renal or hepatic impairment per the FDA label, but eGFR below 30 mL/min/1.73m² warrants closer titration monitoring. [3] A lipid panel is standard for cardiovascular risk stratification in diabetes, consistent with ADA guidance. [4] Thyroid-stimulating hormone (TSH) is often checked in type 1 patients given the co-occurrence of autoimmune thyroid disease.

A urine albumin-to-creatinine ratio (UACR) is recommended annually in all patients with diabetes by the ADA. [4] Vermont Medicaid prior authorization requests for Tresiba typically require documentation of A1C, current diabetes medications, and a clinical note explaining why degludec is preferred over a lower-cost basal insulin. [8]

How to Get a Tresiba Prescription in Vermont: Step-by-Step

Step 1. Choose a prescriber. Any Vermont-licensed MD, DO, NP, or PA may prescribe insulin degludec. Nurse practitioners in Vermont have full independent practice authority under Vermont statute 26 V.S.A. §1572, so no physician co-signature is required. [9] Physician assistants may prescribe under a practice agreement. Telehealth options are listed on the Vermont Blueprint for Health provider directory.

Step 2. Book the visit. In-person options include your primary care provider, a University of Vermont Medical Center (UVMMC) endocrinologist, or a community health center such as the Federally Qualified Health Centers operating under HRSA across Vermont. Telehealth options include national platforms licensed in Vermont. Same-week appointments are often available via telehealth. [5]

Step 3. Complete the clinical assessment. Bring or upload recent lab results (within 90 days), your current medication list, your glucometer or CGM data, and insurance cards. The prescriber will confirm the diagnosis, review hypoglycemia history, and select a starting dose.

Step 4. Manage prior authorization if using insurance. Vermont Medicaid and most commercial plans require PA for Tresiba before dispensing. The PA submission typically needs the diagnosis code (E10.x for type 1, E11.x for type 2), A1C, current diabetes medications, and a statement of medical necessity. [8] The prescriber's office submits this electronically; most Vermont Medicaid PA decisions arrive within 1 to 3 business days for non-urgent requests.

Step 5. Fill the prescription. Once approved, the prescription routes to a retail pharmacy, a Vermont-licensed mail-order pharmacy, or a 503A compounding pharmacy for patients needing a non-standard concentration or formulation. Tresiba is stocked at most major Vermont retail chains and independent pharmacies.

Prior Authorization Requirements for Vermont Medicaid

Vermont Medicaid (Green Mountain Care) covers insulin degludec for both type 1 and type 2 diabetes with prior authorization. The Vermont Department of Vermont Health Access (DVHA) publishes a preferred drug list (PDL) that places Tresiba in a non-preferred tier for basal insulins, meaning a PA is required to demonstrate that a preferred basal insulin (typically insulin glargine U-300 or biosimilar glargine) is either contraindicated, caused adverse effects, or failed to achieve glycemic targets. [8]

Documentation that typically satisfies the PA includes the patient's A1C on prior therapy, a description of hypoglycemia episodes (frequency, severity, need for third-party assistance), and a clinical note. The ADA defines severe hypoglycemia as "an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions." [4] Documented severe hypoglycemia on glargine is among the strongest clinical justifications for a Tresiba PA approval.

Vermont Medicaid PA forms can be submitted through the Vermont DVHA provider portal or by fax. The standard review period is up to 3 business days. Expedited review (24 hours) is available when the prescriber certifies that delay would seriously jeopardize the patient's health. [8]

For commercial insurance, PA criteria vary by plan. Cigna, Blue Cross Blue Shield of Vermont, and MVP Health Care all maintain their own PA requirements. Novo Nordisk's patient assistance program, the NovoCare program, offers Tresiba at a capped cost for commercially insured patients and a free supply for qualifying uninsured patients. [10]

Tresiba Pharmacies in Vermont: Retail, Mail-Order, and 503A Options

Retail pharmacies. CVS, Rite Aid, Hannaford Pharmacy, and independent Vermont pharmacies stock Tresiba FlexTouch pens (100 units/mL and 200 units/mL) and Tresiba vials. Availability varies by location; calling ahead is practical for rural Vermont ZIP codes. [11]

Mail-order and specialty pharmacies. Vermont-licensed mail-order pharmacies can ship Tresiba to any Vermont address with appropriate cold-chain packaging. Mail-order often reduces 90-day supply copays under insurance. The Vermont Board of Pharmacy licenses out-of-state mail-order pharmacies operating in the state, and patients can verify licensure through the Vermont Office of Professional Regulation. [7]

503A compounding pharmacies. Vermont-licensed 503A compounding pharmacies may prepare individualized insulin degludec formulations when a commercially available product does not meet a specific patient's clinical need, for example a different concentration for pediatric dosing or a formulation compatible with an insulin pump. The USP Chapter 797 standards govern sterile compounding at these facilities. [12] A valid prescription from a Vermont-licensed prescriber is required. Not every Vermont 503A pharmacy compounds insulin; patients should confirm with the pharmacy before submitting a prescription. [13]

GoodRx and cash-pay options. For uninsured patients or those awaiting PA approval, GoodRx and manufacturer discount cards reduce out-of-pocket costs at retail pharmacies. NovoCare assistance can bring monthly Tresiba costs to $99 or less for eligible commercially insured patients. [10]

Transferring an Existing Tresiba Prescription to Vermont

A Tresiba prescription written by an out-of-state prescriber cannot simply be transferred to a Vermont pharmacy if the prescriber is not licensed in Vermont. Insulin is a non-controlled prescription drug, so Vermont pharmacy law does not prohibit transferring a prescription between licensed pharmacies within Vermont, but the original prescription must have come from a Vermont-licensed prescriber or a prescriber with a valid Vermont telemedicine encounter on file. [9]

The practical path for new Vermont residents is to schedule a visit (in-person or telehealth) with a Vermont-licensed prescriber who can review the existing regimen and write a new prescription. This visit also allows the prescriber to confirm that the current dose remains appropriate, since insulin requirements can shift with changes in diet, activity, and stress during a move. [4]

If a patient is moving to Vermont and needs a bridge supply, most retail pharmacies can dispense a 30-day emergency supply under Vermont pharmacy board rules while the patient establishes care with a Vermont provider. [9]

Clinical Dosing Reference for Vermont Prescribers

Insulin degludec's flat pharmacokinetics produce a steady-state concentration within 3 to 4 days of initiating a fixed dose. The FDA label recommends titrating every 3 to 4 days, targeting a fasting glucose of 80 to 130 mg/dL per ADA guidance. [3, 4]

For type 2 diabetes patients new to basal insulin, the recommended starting dose is 10 units once daily. For patients converting from insulin glargine U-100 or NPH insulin, a unit-for-unit conversion is appropriate. For patients converting from insulin glargine U-300 (Toujeo), conversion should be unit-for-unit as well, per the FDA label. [3]

The SWITCH 1 and SWITCH 2 crossover trials demonstrated that patients with type 1 and type 2 diabetes achieved equivalent HbA1c reduction on degludec compared to glargine U-100, with statistically significantly fewer nocturnal hypoglycemic episodes (SWITCH 1: rate ratio 0.64 to 95% CI 0.45 to 0.91; SWITCH 2: rate ratio 0.58 to 95% CI 0.40 to 0.84). [14] These data support switching to degludec in Vermont patients reporting recurrent nighttime hypoglycemia on glargine.

A meta-analysis published in Diabetes Care (Ratner et al., 2013) across phase 3 BEGIN trials (pooled N=2,899) found degludec produced a 25% lower rate of overall confirmed hypoglycemia versus glargine U-100 at comparable A1C reductions. [15]

Body weight in clinical trials with degludec increased by a mean of 1.6 kg over 52 weeks in type 1 patients and 2.3 kg in type 2 patients, consistent with other basal insulins and not a distinguishing safety concern. [3]

Pediatric Tresiba Access in Vermont

The FDA expanded the Tresiba indication to include patients aged 1 year and older in 2019, based on the BEGIN Young study. [16] Vermont pediatric endocrinologists at UVMMC and affiliated children's clinics may prescribe degludec for pediatric patients with type 1 diabetes. Telehealth pediatric endocrinology services licensed in Vermont also cover this population.

Vermont's Dr. Dynasaur Medicaid program for children under 19 follows the same DVHA PA process as adult Medicaid. PA approvals in pediatric type 1 patients are often more straightforward because alternative basal options carry higher hypoglycemia burden in growing children with unpredictable activity patterns. [8, 17]

Storage, Handling, and Cold-Chain Considerations for Vermont's Climate

Tresiba pens and vials require refrigeration (36 to 46 degrees Fahrenheit) before first use. After first use, the in-use pen may be kept at room temperature (below 86 degrees Fahrenheit) for up to 56 days, the longest in-use storage period of any commercially available basal insulin. [3] Vermont's winters present the opposite challenge: freezing insulin renders it ineffective. Patients should not store insulin in vehicles during sub-freezing temperatures, a practical concern in Vermont between November and March.

Mail-order deliveries should be scheduled to avoid packages sitting on a doorstep in freezing weather. Most Vermont-licensed mail-order pharmacies offer insulated shipping and will replace a damaged shipment if reported within 24 hours of delivery. [11]

Cost Assistance and Patient Support Programs in Vermont

Novo Nordisk's NovoCare program offers eligible patients a 30-day supply of Tresiba for $35 or a 30-day supply at no cost for qualifying uninsured or underinsured patients. Income eligibility thresholds as of 2025 are set at or below 400% of the federal poverty level for the free supply tier. [10]

Vermont also has the Vermont Prescription Drug Assistance Program (VPharm) for residents who do not qualify for Medicaid but have low income. VPharm supplements copays for insulin and other medications through the Department of Vermont Health Access. [8]

The Insulin Access Law (Act 175, 2020) limits out-of-pocket insulin costs for Vermont-insured patients to $100 per 30-day supply, regardless of the number of vials or pens needed. This cap applies to commercial insurance regulated by the Vermont Department of Financial Regulation and to Vermont Medicaid. [18]

Vermont residents below 300% of the federal poverty level who have coverage gaps may also access insulin through community health centers operating under the 340B drug pricing program, which provides Tresiba and other insulins at significantly reduced cost. [19]